Atıf İçin Kopyala
Senan S., ÖZGÜROĞLU M., Daniel D., Villegas A., Vicente D., Murakami S., ...Daha Fazla
ESMO OPEN, cilt.7, sa.2, 2022 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
7
Sayı:
2
-
Basım Tarihi:
2022
-
Doi Numarası:
10.1016/j.esmoop.2022.100410
-
Dergi Adı:
ESMO OPEN
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
-
Anahtar Kelimeler:
immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy, RANDOMIZED CONTROLLED-TRIAL, PHASE-III, PREOPERATIVE CHEMOTHERAPY, INDUCTION CHEMOTHERAPY, SURGICAL RESECTION, RADIOTHERAPY, N2, SURGERY
-
İstanbul Üniversitesi Adresli:
Hayır
Özet
Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.